Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas

Leukemia

Volumn 23, Issue 3, 2009, Pages 574-580

  Feldman, A L ^a   Law, M ^a   Remstein, E D ^a   Macon, W R ^a   Erickson, L A ^a   Grogg, K L ^a   Kurtin, P J ^a   Dogan, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; INTERFERON REGULATORY FACTOR 4; METHOTREXATE; PREDNISONE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CELL MEDIATED CYTOTOXICITY; CHILD; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC DISORDER; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ONCOGENE; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN TARGETING; RECURRENT DISEASE; SKIN CARCINOMA;

EID: 62549122477     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.320     Document Type: Article

References (49)

1. Jaffe ES, Harris NL, Stein H, Vardiman J. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001.
2. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467-1475.
3. Feldman AL, Sun DX, Law ME, Novak AJ, Attygalle AD, Thorland EC et al Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia 2008; 22: 1139-1143.
4. Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 2006; 20: 313-318.
5. Li R, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 2008; 28: 372-412.
6. Jaffe ES. Anaplastic large cell lymphoma: The shifting sands of diagnostic hematopathology. Mod Pathol 2001; 14: 219-228.
7. Lae ME, Ahmed I, Macon WR. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma. Am J Clin Pathol 2002; 118: 773-779.
8. Droc C, Cualing HD, Kadin ME. Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin. Cancer Control 2007; 14: 124-132.
9. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007; 110: 2259-2267.
10. Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997; 17: 226-230.
11. Feldman AL, Law M, Grogg KL, Thorland EC, Fink S, Kurtin PJ et al. Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization. Am J Clin Pathol 2008; 130: 178-185.
12. Remstein ED, Dogan A, Einerson RR, Paternoster SF, Fink SR, Law M et al. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006; 30: 1546-1553.
13. Remstein ED, Law M, Mollejo M, Piris MA, Kurtin PJ, Dogan A. The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma. Leukemia 2008; 22: 1268-1272.
14. Wiktor AE, Van Dyke DL, Stupca PJ, Ketterling RP, Thorland EC, Shearer BM et al. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genet Med 2006; 8 16-23.
15. Paternoster SF, Brockman SR, McClure RF, Remstein ED, Kurtin PJ, Dewald GW. A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. Am J Pathol 2002; 160: 1967-1972.
16. Einerson RR, Kurtin PJ, Dayharsh GA, Kimlinger TK, Remstein ED. FISH is superior to PCR in detecting t(14;18)(q32;q21)-IgH/bcl-2 in follicular lymphoma using paraffin-embedded tissue samples. Am J Clin Pathol 2005; 124: 421-429.
17. Kurtin PJ, Hobday KS, Ziesmer S, Caron BL. Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. Am J Clin Pathol 1999; 112: 319-329.
18. Roden AC, Macon WR, Keeney GL, Myers JL, Feldman AL, Dogan A. Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: An indolent T-cell lymphoproliferative disorder. Mod Pathol 2008; 21: 455-463.
19. Barch M, Knutsen T, Spubeck J (eds). The AGT Cytogenetics Laboratory Manual. Lippincott-Raven: Philadelphia, PA, 1997.
20. Roncador G, Garcia JF, Maestre L, Lucas E, Menarguez J, Ohshima K et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/ lymphoma. Leukemia 2005; 19: 2247-2253.
21. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ et al. ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 1998; 91: 2076-2084.
22. Boulland ML, Wechsler J, Bagot M, Pulford K, Kanavaros P, Gaulard P. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins. Histopathology 2000; 36: 136-144.
23. Kummer JA, Vermeer MH, Dukers D, Meijer CJ, Willemze R. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol 1997; 109: 636-640.
24. Felgar RE, Salhany KE, Macon WR, Pietra GG, Kinney MC. The expression of TIA-1+ cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): Correlation with morphology, immunopheno-type, ultrastructure, and clinical features. Hum Pathol 1999; 30: 228-236.
25. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM et al ALK - anaplastic large-cell lymphoma is clinically and immuno-phenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496-5504.
26. Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: A report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-3661.
27. ten Berge RL, de Bruin PC, Oudejans JJ, Ossenkoppele GJ, van der Valk P, Meijer CK. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 2003; 43: 462-469.
28. Salaverria I, Bea S, Lopez-Guillermo A, Lespinet V, Pinyol M, Burkhardt B et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 2008; 140: 516-526.
29. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker S. Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003; 37: 176-185.
30. Thompson MA, Stumph J, Henrickson SE, Rosenwald A, Wang Q, Olson S et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol 2005; 36: 494-504.
31. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084-2092.
32. Chesi M, Kuehl WM, Bergsagel PL. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma. Ann Oncol 2000; 11 (Suppl. 1): 131-135.
33. Tamura A, Miura I, Iida S, Yokota S, Horiike S, Nishida K et al. Interphase detection of immunoglobulin heavy chain gene translocations with specific oncogene loci in 173 patients with B-cell lymphoma. Cancer Genet Cytogenet 2001; 129: 1-9.
34. Michaux L, Wlodarska I, Rack K, Stul M, Criel A, Maerevoet M et al Translocation t(1;6)(p35.3;p25.2): A new recurrent aberration in 'unmutated'; B-CLL. Leukemia 2005; 19: 77-82.
35. Mecucci C, Michaux JL, Tricot G, Louwagie A, den Berghe H. Rearrangements of the short arm of chromosome no. 6 in T-cell lymphomas. Leuk Res 1985; 9: 1139-1148.
36. Ott G, Katzenberger T, Siebert R, DeCoteau JF, Fletcher JA, Knoll JH et al. Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: Infrequent detection of the t(2;5) in extranodal lymphomas. Genes Chromosomes Cancer 1998; 22: 114-121.
37. Mitelman F, Johansson B, Mertens F (eds). Mitelman Database of Chromosome Aberrations in Cancer (http://cgap.nci.nih.gov/Chromosomes/Mitelman2007).
38. Pekarsky Y, Hallas C, Isobe M, Russo G, Croce CM. Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci USA 1999; 96: 2949-2951.
39. Almire C, Bertrand P, Ruminy P, Maingonnat C, Wlodarska I, Martin-Subero JI et al. PVRL2 is translocated to the TRAlocus in t(14;19)(q11;q13)-positive peripheral T-cell lymphomas. Genes Chromosomes Cancer 2007; 46: 1011-1018.
40. Leich E, Haralambieva E, Zettl A, Chott A, Rudiger T, Holler S et al Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas. J Pathol 2007; 213: 99-105.
41. Tsuboi K, Iida S, Inagaki H, Kato M, Hayami Y, Hanamura I et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000; 14: 449-456.
42. Natkunam Y, Warnke RA, Montgomery K, Falini B, Van De Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001; 14: 686-694.
43. Wasco MJ, Fullen D, Su L, Ma L. The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders. Hum Pathol 2008; 39: 557-563.
44. Iqbal J, Greiner TC, Patel K, Dave BJ, Smith L, Ji J et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007; 21: 2332-2343.
45. Kempf W, Kutzner H, Cozzio A, Sander CA, Pfaltz MC, Muller B et al MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: A valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Br J Dermatol 2008; 158: 1280-1287.
46. Zhao WL, Liu YY, Zhang QL, Wang L, Leboeuf C, Zhang YW et al. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood 2008; 111: 3867-3871.
47. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
48. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 4293-4297.
49. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-3065.